Dendritic cell based vaccination strategy: an evolving paradigm by Filley, Anna C. & Dey, Mahua
Dendritic cell based vaccination strategy: an evolving paradigm
Anna C. Filley1 and Mahua Dey1,2
1Department of Neurosurgery, Indiana University School of Medicine, Indianapolis, IN, USA
2Indiana University Purdue University Indianapolis (IUPUI), 320 W 15th Street, Neuroscience 
Building NB400A, Indianapolis, IN 46202, USA
Abstract
Malignant gliomas (MG), tumors of glial origin, are the most commonly diagnosed primary 
intracranial malignancies in adults. Currently available treatments have provided only modest 
improvements in overall survival and remain limited by inevitable local recurrence, necessitating 
exploration of novel therapies. Among approaches being investigated, one of the leading 
contenders is immunotherapy, which aims to modulate immune pathways to stimulate the selective 
destruction of malignant cells. Dendritic cells (DCs) are potent initiators of adaptive immune 
responses and therefore crucial players in the development and success of immunotherapy. 
Clinical trials of various DC-based vaccinations have demonstrated the induction of anti-tumor 
immune responses and prolonged survival in the setting of many cancers. In this review, we 
summarize current literature regarding DCs and their role in the tumor microenvironment, their 
application and current clinical use in immunotherapy, current challenges limiting their efficacy in 
anti-cancer therapy, and future avenues for developing successful anti-tumor DC-based vaccines.
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Introduction
It has been established that natural antitumor immune responses develop in a variety of 
cancer types, primarily mediated by CD8+ cytotoxic lymphocytes (CTLs) and CD4+ T 
helper-1 (Th1) cells [1–3]. However, these responses are often insufficient to completely 
eliminate tumor presence and may be overcome by tumor-induced immunosuppression [3, 
4]. Based on these observations, cancer immunotherapy aims to modulate immune pathways 
to initiate or augment otherwise inadequate anti-tumor immune responses. One promising 
approach is through therapeutic vaccination, whereby immune cells such as dendritic cells 
(DCs) are sensitized to tumor-associated antigens (TAAs) and stimulated to mobilize 
effector responses resulting in selective destruction of malignant cells.
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DCs are bone marrow-derived lymphoid cells uniquely capable of activating primary 
immune responses through the presentation of antigens to naïve CD4+ and CD8+ T cells [1, 
5]. Through the release of interleukin-15 (IL-15), DCs stimulate the development of memory 
T cells and lasting protective immunity. DCs are also potent activators of B cells, natural 
killer (NK), and natural killer T (NKT) cells [5]. In the steady-state, DCs reside in peripheral 
tissues, internalizing antigens from their surrounding environment. These antigens are 
degraded into short peptide fragments, loaded onto major histocompatibility complex 
(MHC) molecules to form peptide-MHC (p-MHC) complexes, and displayed on the DC’s 
surface. Following exposure to pathogenic or inflammatory molecules, DCs mature and 
migrate to secondary lymphoid organs to activate T cells [1]. Antigen presentation by 
immature DCs induces antigen-specific tolerance, a pathway crucial in preventing 
autoimmunity and often exploited by tumors to avoid elimination by the immune system [6, 
7]. As crucial modulators of innate and adaptive immune responses, DCs provide a 
promising foundation for immunotherapy.
Malignant gliomas (MGs), tumors of glial origin, are the most frequently diagnosed primary 
intracranial malignancies in adults. The most common, and most aggressive, subtype of MG 
is glioblastoma (GBM). The prognosis for patients with GBM is extremely poor, with 
median life expectancy of 14.6 months and 5-year survival rates less than 10% [8, 9]. The 
current standard treatment for MG is maximal surgical resection followed by radiotherapy 
and temozolamide (TMZ) [9]. However, these nonspecific therapies are limited by systemic 
toxicities and damage to healthy surrounding tissues and ultimately fail to result in 
complete, sustained tumor eradication. There is therefore a great need to explore novel 
approaches, such as immunotherapy, to improve outcomes for these patients.
Immunotherapy in the context of MG is a highly evolving field that has shown significant 
promise in pre-clinical and early clinical testing. With a better understanding of cancer 
antigens on a basic genomic level and growing knowledge of immune checkpoint pathways, 
the last several years have seen great advancements in the fields of cancer immunology and 
immunotherapy. Understanding these recent developments is critical in designing the next 
generation of successful anti-glioma DC-based vaccines.
Dendritic cell biology
DC subtypes and DC trafficking
DCs are a morphologically and functionally heterogeneous group of cells derived from 
CD34+ hematopoietic progenitor cells in the bone marrow. There are two distinct subtypes 
of human DCs: a larger subset of CD11c+ “myeloid” dendritic cells (mDCs), and a smaller 
subset of CD11c-“plasmacytoid” dendritic cells (pDCs). Both mDCs and pDCs are antigen-
presenting cells (APCs) and can activate T cells, though they differ in tissue distribution, 
surface molecule expression, and cytokine release [1].
mDCs are found in most lymphoid and nonlymphoid tissues and tend to be potent 
stimulators of cell-mediated immunity. Activated mDCs release IL-12, which induces IFN-γ 
secretion and CD4+ Th1 differentiation, promoting Th1-mediated antitumor responses [10, 
11]. Present in secondary lymphoid organs, pDCs have the unique ability to produce large 
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amounts of interferon-α (IFN-α) in response to viral infection. They express Toll-like 
receptor-7 (TLR-7) and TLR-9 to recognize viral nucleic acids [5, 12]. Type I IFNs, like 
IFN-α, are potent activators of antiviral and antitumor responses.
Following development in the bone marrow, immature mDCs and pDCs disperse throughout 
the body, guided by chemokines such as MIP-1α, MIP-1β, RANTES, MCP-3, and MIP-5. 
Detection of pathogenic or inflammatory molecules stimulates DC trafficking to sites of 
infection or tissue damage [1].
Molecules expressed by DCs
DCs express surface molecules specialized for T cell interactions including antigen 
presentation (CD1 and MHC class I and II), costimulatory (CD80/B7.1 and CD86/B7.2), 
and adhesion (CD11, CD50, CD54, CD58) molecules [2]. Present on most cells, MHC class 
I molecules display internally derived antigens, including self and viral peptides, to CD8+ T 
cells. Unique to APCs, MHC class II molecules present exogenous peptides to CD4+ T 
cells. Antigens captured by DCs are typically loaded onto MHC class II molecules, but may 
be targeted to MHC class I molecules and presented to CD8+ T cells in a process termed 
“cross-presentation.”[1, 13] CD1 molecules present endogenous and exogenous lipid 
antigens [1]. DCs also express a variety of intracellular and extracellular receptors through 
which they sense antigens, chemokines, and activating stimuli in their environment. Among 
these are C-type lectin receptors (DEC-205, DC-SIGN), Fcγρεχεπτορσ (CD64, CD32), 
integrins, TLRs, TNF-family receptors, cytokine and chemokine receptors, and scavenger 
receptors [1, 13].
Mature versus immature DCs
Immature DCs are specialized for antigen sampling and express high concentrations of 
receptors mediating antigen recognition and uptake. They reside in peripheral tissues, 
continuously internalizing antigens from their environment. However, in this immature state 
they express low levels of surface MHC and costimulatory molecules and therefore are 
inefficient antigen presenting cells and poor initiators of T cell activation [7]. Detection of 
pathogenic or inflammatory molecules, such as LPS or TNF-α, initiates DC maturation, 
leading to an enhanced ability to activate T cells. Maturing DCs downregulate receptors 
specialized for antigen uptake, upregulate surface expression of MHC and costimulatory 
molecules, and undergo cytoskeletal changes to improve motility and maximize surface area 
for T cell interactions. Maturation also induces DCs to secrete cytokines, chemokines, and 
growth factors to attract other immune cells and promote the activation, proliferation, and 
differentiation of effector cells. Pathogenic molecules and other tissue factors present during 
maturation influence the specific cytokine release profile of mature DCs [7]. Activated DCs 
upregulate CCR7 expression and migrate to the paracortex of draining lymph nodes, 
attracted by chemokines MIP-3β and SLC [1, 7]. Here, DCs receive the final stimulus for 
their maturation: ligation of surface CD40 molecules by T cell CD40 ligand. CD40/CD40L 
interactions further increase DC costimulatory molecule expression and cytokine secretion, 
strengthening DC-T cell interactions and effector responses [1, 2].
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Immunogenic versus tolerogenic DCs
Antigen presentation to naïve T cells has the potential to result in antigen-specific immunity 
or antigen-specific tolerance [7]. Although both mature and immature DCs are capable of 
antigen presentation, only mature DCs possess the high levels of surface MHC and 
costimulatory molecules necessary to activate naïve T cells. Antigen presentation by 
immature or incompletely matured DCs leads to antigen-specific tolerance by inducing T 
cell anergy, apoptosis, or differentiation into immunosuppressive regulatory T (Treg) cells 
[14].
DC-mediated generation of antigen-specific tolerance is fundamental in preventing 
autoimmune destruction of self-proteins. During T cell development in the thymus, DCs 
induce clonal deletion of strongly self-reactive double-positive thymocytes in a process 
termed “negative selection.”[6] However, not all self-antigens are present in the thymus and 
some are only expressed later in life. The identification and removal of T cells with receptors 
specific for these antigens is mediated peripherally by immature DCs. Early development of 
self-tolerance is especially important given that in sites of inflammation, DCs are exposed to 
both self and non-self antigens in an activating environment. A tolerogenic state also occurs 
in a variety of tumor types, allowing malignant cells to evade detection and elimination by 
the immune system [3, 4].
DC-T cell interaction (Fig. 1)
Within secondary lymphoid tissues, DCs present antigens to naïve T cells. This encounter is 
characterized by several key interactions, illustrated in Fig. 1. The strength and nature of the 
elicited response is determined by the state of DC maturation, concentration of p-MHC 
complexes, affinity of T cell receptors for p-MHC complexes, type and strength of B7 
interactions, and presence of local cytokines. Of particular interest to cancer immunotherapy 
is the polarization of T cell differentiation. Th1 cells secrete pro-inflammatory cytokines to 
activate downstream effector responses and support CD8+ CTL maturation, forming the 
basis for antitumor immunity, whereas Th2 and Treg responses are not cytotoxic, impair 
Th1-mediated tumor destruction, and allow tumor persistence [10]. Gradual dysfunction of 
Th1-mediated cellular immunity and the development of Th2 and Treg responses are 
associated with cancer progression and a poor prognosis in many malignancies [15, 16].
DC in tumor microenvironment
Role of DCs in various cancers
DCs are naturally exposed to a variety of antigens within the tumor microenvironment. 
These tumor-associated antigens (TAAs) may be uniquely tumor-specific (MAGE, BAGE, 
GAGE), viral (HPV, CMV), tissue-specific differentiation antigens (MART-1, gp100, 
tyrosinase), or mutated and/or overexpressed self-proteins (HER-2/neu, EGFRvIII) [17, 18]. 
Chemotherapy and radiation, standard components of anticancer treatment, trigger 
widespread tumor cell death further promoting TAA release [19]. These antigens can be 
captured by tumor-infiltrating DCs and presented to naïve T cells to initiate antigen-specific 
antitumor responses.
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However, many tumors employ mechanisms to avoid immune-mediated rejection. Malignant 
cells may develop reduced immunogenicity through mutations of TAAs, defects in antigen 
processing or presentation, or downregulation of MHC class I expression [4]. Tumors also 
actively promote the development of a tolerogenic environment, suppressing the 
effectiveness of antitumor immune responses through the release of immunosuppressive 
cytokines, modulation of immune checkpoint pathways, and attraction of 
immunosuppressive leukocytes. Many tumors overexpress the STAT3 protein, which 
prevents tumor cell apoptosis, downregulates MHC and costimulatory molecule expression, 
promotes immunosuppressive cytokine release, inhibits IL-12 and IFN-γ expression, and 
suppresses Th1 immune responses [20]. Tumors also contain an abundance of compounds 
known to inhibit DC maturation and function, including IL-10, TGF-β, VEGF, IL-6, and 
PGE2 [21]. DCs in tumor-bearing patients often express an immature or incompletely 
matured phenotype and have a reduced capacity to activate antitumor immune responses, 
instead promoting Treg cell development and antigen-specific tolerance [21].
Role of DC in glioma
A prominent feature of MG is profound suppression of cell-mediated immunity [22]. 
Gliomas often contain high proportions of apoptotic and dysfunctional T lymphocytes [22, 
23]. T cells obtained from patients with MG demonstrate defective signaling, impaired 
cytokine release, and a diminished ability to proliferate and carry out effector responses 
[22]. Gliomas actively suppress T cell function by modulating inhibitory checkpoint 
pathways and releasing immunosuppressive cytokines like TGF-β and IL-10 [22]. TGF-β 
inhibits the activation, proliferation, and differentiation of effector T cells [4] and is 
independently associated with a poor prognosis in MG [24]. Often overexpressed by 
malignant cells and tumor-infiltrating DCs, programmed-death-ligand-1 (PD-L1) binds to 
PD-1 molecules on activated T cells to induce their anergy and apoptosis. T cells can also be 
stimulated to express CTLA-4, which competes with CD28 molecules for binding to DC 
CD80/CD86 and sends inhibitory signals to T cells, preventing their activation [25]. 
CTLA-4 interactions with DCs can induce DC expression of indoleamine-2,3-deoxygenase 
(IDO), an enzyme involved in tryptophan catabolism, which arrests T cell proliferation, 
induces T cell apoptosis, and promotes Treg cell generation [13, 25]. IDO overexpression is 
observed in aggressively growing tumors and associated with reduced effector T cell 
infiltrations [25].
The dysfunction exhibited by T cells of glioma patients occurs in APCs as well. This 
concept can be illustrated by exploring the role of pDCs in glioma development and 
progression. Both animal models and human clinical trials have demonstrated that pDCs can 
induce antitumor immune responses through T cell activation and IFN-α production [12, 
13]. However, other studies have associated pDC tumor infiltration with disease progression 
and a poor prognosis [26, 27]. These findings can be attributed to the systemic dysfunction 
of pDCs often observed in the setting of cancer. Tumor-associated pDCs exhibit a reduced 
capacity to secrete IFN-α, likely due to downregulation of TLR-9, and impaired antigen 
presentation. These pDCs are poor initiators of antitumor immunity and promote Treg cell 
development [12, 26, 27]. Our group has shown that in a murine model of glioma, selective 
pDC depletion in the early stages of tumor formation reduces Treg cell presence and 
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prolongs survival [26]. Patients with glioma possess greater proportions of Treg cells, the 
accumulation of which are associated with suppression of antitumor responses and a poor 
prognosis [16, 27–29]. Selective Treg cell depletion has been shown to restore effector cell 
functions, augment antitumor immune responses, and improve survival outcomes in many 
cancers [30, 31].
DC based theraputic vaccine
As crucial regulators of innate and adaptive immune responses, DCs provide a solid 
foundation for the development of immunotherapies. DC-based immunotherapies 
manipulate DCs to initiate immune responses against TAAs. Numerous preclinical studies 
have established the ability of various DC-based vaccinations to induce robust and highly 
specific antitumor T cell responses, leading to prolonged survival and protective antitumor 
immunity in animal models [32–34]. Initially evaluated in human clinical trials in the 1990s, 
DC-based vaccines were shown to be beneficial in the treatment of patients with B-cell 
lymphoma [35], melanoma [36], and prostate cancer [37]. In the years since, DC-based 
vaccines have been adapted and studied in a variety of other malignancies, listed in Table 1 
[35–48]. The first patient with a primary intracranial tumor treated with DC-based 
immunotherapy is described in a case report published in 2000 by Liau et al. Following 
surgical resection, this patient received three immunizations of autologous DCs pulsed with 
allogeneic MHC class I glioblastoma peptides as treatment for recurrent brainstem GBM. 
The vaccine was well tolerated and the patient developed measurable cellular immune 
responses against vaccine antigens, however an objective clinical response was not evident 
[49]. Results of early clinical trials, listed in Table 2, have since confirmed the safety, 
feasibility, and immune-stimulating activity of DC-based immunotherapy in patients with 
MG [24, 28, 29, 49–64]. Given its reliance on final effector functions of the immune system, 
a concern with immunotherapy is its efficacy in conjunction with lymphocyte-depleting 
treatments, like chemotherapy. In subsequent studies of DC-based immunotherapy in 
combination with standard treatment for MG, vaccinated patients receiving concurrent TMZ 
demonstrated enhanced humoral and cellular antitumor responses correlating with prolonged 
survival, confirming the efficacy of immunotherapy in a lymphopenic environment [57]. 
There are two well-established avenues for introducing antigens to DCs: direct targeting of 
antigens to DCs in vivo and ex vivo generation of antigen-loaded DCs [5, 13].
In vivo DC targeting
The targeted delivery of antigens to DCs in vivo can be achieved by coupling antigens to 
antibodies specific to DC surface molecules like C-type lectins, Fcγ, MHC class II, or CD40 
[65, 66]. As different DC receptors have differential influences on the capacity of mature 
DCs to polarize T cell differentiation, this method allows targeting of specific receptors 
known to stimulate DC-mediated induction of Th1 responses [27]. However, a major 
limitation of this approach is the possibility of antigen uptake by immature DCs, leading to 
the induction of tolerogenic responses [65, 66]. This risk is especially relevant for cancer 
patients, who may suffer from immune system dysfunction induced by tumor-secreted 
factors or chemotherapy or radiation treatments. Concurrent administration of DC 
maturation activators, such as TLR ligands or CD40 agonists, can minimize this risk [66].
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Ex-vivo generated DCs
Autologous DCs can be generated and expanded ex vivo, charged with TAAs, exposed to 
maturation stimuli, and then reintroduced into the patient as a vaccine. DCs may be directly 
isolated from the peripheral blood or differentiated in vitro from monocytes or CD34+ 
hematopoietic progenitor cells. The most widely used method involves the in vitro 
differentiation of peripheral blood monocytes in the presence of GM-CSF and IL-4 [67]. 
DCs may be exposed to antigens in the form of peptides or proteins, whole killed tumor cells 
or lysates, tumor stem cells, mRNA or cDNA encoding TAAs, or through direct fusion with 
tumor cells, and subsequently cultured with molecules to induce maturation. Among those 
commonly used are TNF-α, IL-1β, IL-6, PGE2, LPS, and IFN-γ [21, 68, 69].
Antigen selection introduces unique benefits and limitations to vaccine generation and 
efficacy. Commonly used in clinical trials, peptide antigens can be generated for key 
sequences of tumor-specific proteins, modified to enhance immunogenicity, and targeted 
directly to DC surface MHC molecules in culture [5]. Their known structure facilitates 
monitoring of antigen-specific immune responses, however limits their use to patients with 
HLA subtypes possessing inherent affinity for these sequences; in a recent clinical trial of 
DC-based vaccination with glioma-associated antigens (GAAs), HLA subtype restrictions 
only allowed for treatment of 40% of initially enrolled patients [29]. Larger proteins and 
tumor mRNA molecules must be internalized and processed by DCs, allowing the selection 
and presentation of a variety of epitopes compatible with the patient’s own HLA type, 
though the sequences selected may not be strongly immunogenic [2]. Whole tumor lysates, 
tumor stem cells, and tumor cell-DC fusion vaccines expose DCs to a tumor’s unique, 
complete antigen profile without the need for individual antigen identification, which may 
be useful in highly heterogeneous tumors and those in which specific TAAs are unknown. 
However, this type of vaccine depends on the availability of autologous tumor material, 
which may be limited in patients having undergone previous treatments.
Ex vivo DC generation is expensive, labor-intensive, and must be personalized for individual 
patients. Optimization of in vitro conditions to yield high-quality DCs capable of inducing 
strong cytotoxic responses in vivo remains a topic of continued research [21, 68, 70, 71]. 
Despite these challenges, ex vivo DC generation offers greater control over the phenotype 
and quality of DCs and their encounter with antigen. Expanded and matured away from 
tumor-induced immunosuppression, these DCs are poised to activate tumor-specific 
immunity rather than tolerance and may be particularly useful in patients with weakened 
immune systems that cannot respond to in vivo delivered stimuli [5, 21].
Limitations of DC based vaccine
The field of immunotherapy has seen significant advancements over the past decade. DC-
based vaccination is well tolerated and induces systemic antitumor responses and prolonged 
survival in a subset of vaccinated patients with a variety of tumor types. However, objective 
clinical response rates remain low, leaving much room for improvement. Furthermore, 
comparing results between clinical trials has been limited by variability in vaccine 
composition and preparation and lack of established criteria for objective evaluation of 
immunological and clinical responses.
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Selection of optimal conditions for vaccine development to generate high-quality DCs 
capable of inducing robust antitumor immune responses remains a significant area of 
research. Recent reports suggest that DCs matured ex vivo are less effective than their 
natural counterparts in activating T cells and inducing effective antitumor immunity [68, 71]. 
Also fundamental to the development of DC-based vaccines is the selection of immunogenic 
antigens with which to prime the immune system. This is limited by the heterogeneous 
antigen profile of MG, both between patients and within individual tumors [5]. Vaccination 
also introduces selective pressures for tumor antigenic mutation and the development of 
antigen-loss variants, particularly with single-antigen vaccines and those targeting antigens 
non-essential for cell survival [13]. Emergence of antigen-negative metastases following 
DC-based vaccination has been documented in several studies [38, 64]. Another 
complication associated with immune system manipulation is the unintentional activation of 
effector responses against self-proteins. Although uncommon, autoimmune responses have 
occurred following immunotherapy. Most notably, the development of vitiligo has been 
observed in several patients receiving DC-based vaccination for metastatic melanoma [39, 
41, 46].
Tumor-induced immunosuppression remains one of the greatest challenges currently facing 
immunotherapy. Through elaboration of cytokines like IL-10 and TGF-β, induction of 
negative checkpoint regulators such as CTLA-4 and PD-L1, recruitment of 
immunosuppressive leukocytes, and downregulation of tumor cell immunogenicity, tumors 
evade immune detection, suppress DC and effector cell function, and limit the efficacy of 
DC-based vaccination [4, 5].
Ways to overcome limitations and future direction
The effectiveness of DC-based immunotherapy hinges on an ability to stimulate robust 
antigen-specific CD4+ and CD8+ effector responses that are not overcome by tumor-
induced immunosuppression. Our group has shown that in a murine model of glioma, mDCs 
and pDCs behave differently in DC-based anti-glioma vaccines, significantly impacting the 
resulting antitumor immune response. These results demonstrate the importance of selecting 
an optimal DC subtype during vaccination development, and specifically that using natural 
mDCs and selectively depleting pDCs can enhance the efficacy of DC-based immunotherapy 
[26].
The ideal vaccine antigen is unique to malignant cells, commonly expressed between 
patients and within individual tumors, crucial to tumor survival, and not restricted to certain 
HLA subtypes. Although the molecular heterogeneity of MGs has complicated the 
identification of tumor-specific antigens, clinical trials targeting antigens like TRP-2, gp100, 
MAGE-1, HER2, and CMV pp65 have demonstrated success and continue to be investigated 
(NCT02366728, NCT02465268) [29, 50, 61, 64]. Peptide antigens can also be modified to 
increase affinity for MHC molecules, promote immune cell activation, or enhance 
immunogenicity, particularly for overexpressed self-antigens to which the immune system 
has developed tolerance [40]. Sipuleucel-T, a DC-based vaccine utilizing a recombinant 
antigen-GM-CSF fusion protein, has significantly advanced the treatment of metastatic 
prostate cancer, extending overall survival by 4.1 months [48]. Other vaccine trials focus on 
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whole tumor materials, which allow DCs of any HLA subtype to be loaded with multiple 
antigens expressed within an individual tumor [28, 51–60, 62, 63]. Targeting multiple 
antigens or epitopes reduces tumor selection for antigen-loss variants [13]. Phase III clinical 
trials of DC-based vaccination utilizing autologous tumor lysate in patients with MG are 
currently ongoing (NCT00045968, NCT02146066).
Targeting multiple immune pathways through combination therapy has potential to induce a 
multi-faceted response that is more effective than DC-based vaccination alone. Combination 
treatment with radiotherapy and chemotherapy has been shown to enhance the efficacy of 
DC-based vaccination in preclinical studies and human clinical trials [57, 63, 72]. In 
addition to direct killing of tumor cells, these therapies stimulate immune responses that 
complement the antitumor effects of DC-based immunotherapy [73]. Both modalities 
increase tumor cell immunogenicity and susceptibility to immune-mediated destruction by 
upregulating the expression of MHC, costimulatory, and adhesion molecules, stress ligands, 
and death receptors. Through induction of DNA damage and ER stress, they stimulate a 
particularly inflammatory form of cell death, releasing TAAs, cytokines, chemokines, and 
other immune-stimulating danger signals that attract DCs, leading to the activation of 
adaptive immune responses [73]. Combination with other immune-modulating treatments 
like oncolytic virotherapy or adoptive T cell transfer has potential to further enhance 
immune responses to DC-based immunotherapy. Vaccine efficacy may also be improved 
with the addition of immunogenic adjuvants or stimulators of APC function. Imiquimod, a 
TLR-7 agonist, and poly-ICLC, a TLR-3 agonist, enhance DC survival and trafficking to 
lymphoid tissues [28, 61, 74]. IL-12, fundamental in the generation of antitumor immunity, 
has also been shown to augment DC-based vaccine effectiveness [55, 75]. IL-2, a potent 
stimulator of T cell proliferation, has shown some immunotherapeutic promise, however its 
effectiveness is limited by a propensity to promote Treg cell development [27, 47, 70].
Mitigating tumor-induced immunosuppression will be fundamental in the development of 
the next generation of DC-based vaccines. This can be accomplished through neutralization 
of immunosuppressive cytokines, blockade of negative regulators of T cell function, or 
depletion of immunosuppressive cells. Antibody-mediated inhibition of CTLA-4 has 
augmented antitumor responses in animal models and human clinical trials and, in 
combination with intratumoral IL-12, dramatically reduced Treg cell presence and increased 
the proportion of functional effector T cells in patients with MG [74]. However, its use is 
limited by systemic toxicity and life-threatening autoimmune responses secondary to 
unrestricted T cell activation [76]. Human clinical trials of MDX-1106, an anti-PD-1 
monoclonal antibody, demonstrated evidence of clinical efficacy in the treatment of 
advanced metastatic cancers and exhibited a more favorable side effect profile than CTLA-4 
inhibitors [77]. PD-1 inhibition continues to be investigated in clinical trials for MG 
(NCT02423343, NCT02529072). A recent phase I trial of simultaneous PD-1 and CTLA-4 
inhibition in patients with advanced melanoma has shown significant promise as a 
combination therapy, with 65% of patients showing evidence of antitumor responses to 
vaccination and 53% of patients experiencing significant tumor regression of 80% or more 
[78]. A phase II clinical trial investigating simultaneous CTLA-4 and PD-1 inhibition in 
patients with MG is currently ongoing (NCT02794883).
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Results of multiple clinical trials have established the ability of DC-based immunotherapy to 
induce strong antigen-specific antitumor immune responses and prolong survival in a variety 
of malignancies, including MG. However, these benefits are still not realized in the majority 
of vaccinated patients. While the induction of antitumor effector responses is an important 
endpoint of vaccination, fully addressing complex elements such tumor-induced 
immunosuppression remains a significant challenge in the development of effective 
immunotherapies. In addition, effect of epigenetics on immune system has to be taken into 
consideration to predict vaccine mediated immune activation at a personal level. Moving 
forward, future of DC cancer vaccination will include rewiring DC molecular pathways and 
targeting natural DCs both in vivo and ex vivo to generate mature activated DCs that are 
refractory to tumor induced immunosuppression. Ultimately, the best outcomes will likely 
be seen in the setting of combination therapies that generate a multi-faceted approach to 
tumor destruction in terms of activating the effector arm and suppressing the regulatory arm 
of the immune system.
Acknowledgments
This work is supported by NIH NRCDP-K12 and NINDS K08 NS092895 Grant (MD). Authors would like to thank 
Christopher Brown MS, for his assistance with the image illustrations.
References
1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YG, Pulendran B, Palucka K. 
Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767–811. [PubMed: 10837075] 
2. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999; 
5:507–529.
3. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat 
Rev Cancer. 2005; 5(4):263–274. [PubMed: 15776005] 
4. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by 
tumor cells. Annu Rev Immunol. 2007; 25:267–296. [PubMed: 17134371] 
5. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near 
future. Int J Cancer. 2001; 94(4):459–473. [PubMed: 11745430] 
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 
2003; 21:685–711. [PubMed: 12615891] 
7. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce 
tolerance or immunity? Trends Immunol. 2002; 23(9):445–449. [PubMed: 12200066] 
8. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, 
Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide 
versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year 
analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459–466. [PubMed: 19269895] 
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, 
Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. N Engl J Med. 2005; 352(10):987–996. [PubMed: 15758009] 
10. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani 
N, Schuler G. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development 
as well as interferon-gamma production by T helper 1 cells. Eur J Immunol. 1996; 26(3):659–668. 
[PubMed: 8605935] 
11. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the 
immune system decide to mount a helper T-cell response? Immunology. 2008; 123(3):326–338. 
[PubMed: 17983439] 
Filley and Dey Page 10
J Neurooncol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AKMG, Foulad D, Kroeger 
KM, Barnett N, Josien R, et al. Plasmacytoid dendritic cells in the tumor microenvironment: 
immune targets for glioma therapeutics. Neoplasia. 2012; 14(8):757–770. [PubMed: 22952428] 
13. O’Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active 
immunotherapy of cancer. Blood. 2004; 104(8):2235–2246. [PubMed: 15231572] 
14. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of 
effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001; 
193(2):233–238. [PubMed: 11208863] 
15. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye JP, Sica A, Young HA, Wiltrout 
RH, Ochoa AC. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor 
growth. J Natl Cancer Inst. 1995; 87(19):1478–1483. [PubMed: 7674335] 
16. Grauer OM, Nierkens S, Bennink E, Toonen LWJ, Boon L, Wesseling P, Sutmuller RPM, Adema 
GJ. CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and 
efficiently suppress antiglioma immune responses in vivo. Int J Cancer. 2007; 121(1):95–105. 
[PubMed: 17315190] 
17. Boon T, Coulie PG, vandenEynde. Tumor antigens recognized by T cells. Immunol Today. 1997; 
18(6):267–268. [PubMed: 9190110] 
18. Stewart, B., Wild, CP. World cancer report 2014. International agency for research on cancer, 
WHO; Geneva: 2014. 
19. Melief CJM. Cancer immunotherapy by dendritic cells. Immunity. 2008; 29(3):372–383. [PubMed: 
18799145] 
20. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. 
Nat Rev Cancer. 2009; 9(11):798–809. [PubMed: 19851315] 
21. Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to 
tumors. Semin Immunol. 2010; 22(3):173–182. [PubMed: 20409732] 
22. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with 
primary malignant brain tumors. J Neuroimmunol. 1999; 100(1–2):216–232. [PubMed: 10695732] 
23. Walker DG, Chuah T, Rist MJ, Pender MP. T-cell apoptosis in human glioblastoma multiforme: 
implications for immunotherapy. J Neuroimmunol. 2006; 175(1–2):59–68. [PubMed: 16631933] 
24. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, 
Mischel PS, Cloughesy TF, et al. Dendritic cell vaccination in glioblastoma patients induces 
systemic and intracranial T-cell responses modulated by the local central nervous system tumor 
microenvironment. Clin Cancer Res. 2005; 11(15):5515–5525. DOI: 
10.1158/1078-0432.CCR-05-0464 [PubMed: 16061868] 
25. Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, Lesniak MS, Wainwright DA. The role of 
IDO in brain tumor immunotherapy. J Neurooncol. 2015; 123(3):395–403. [PubMed: 25519303] 
26. Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, Pytel P, Han Y, Tobias 
A, Zhang LJ, et al. Dendritic cell-based vaccines that utilize myeloid rather than plasmacytoid 
cells offer a superior survival advantage in malignant glioma. J Immunol. 2015; 195(1):367–376. 
[PubMed: 26026061] 
27. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):
265–277. [PubMed: 22437871] 
28. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene 
expression profile correlates with T cell infiltration and relative survival in glioblastoma patients 
vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011; 17(6):1603–1615. DOI: 
10.1158/1078-0432.CCR-10-2563 [PubMed: 21135147] 
29. Prins RM, Wang XY, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, et 
al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-
loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013; 36(2):152–
157. DOI: 10.1097/CJI.0b013e3182811ae4 [PubMed: 23377664] 
30. Casares N, Arribillaga L, Sarobe P, Dotor J, de Cerio ALD, Melero I, Prieto J, Borras-Cuesta F, 
Lasarte JJ. CD4(+)/CD25(+) regulatory cells inhibit activation of tumor-primed CD4(+) T cells 
with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity 
elicited by peptide vaccination. J Immunol. 2003; 171(11):5931–5939. [PubMed: 14634104] 
Filley and Dey Page 11
J Neurooncol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
31. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune 
responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci. 2009; 
1174:99–106. [PubMed: 19769742] 
32. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic 
cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous 
system tumors. J Exp Med. 1997; 186(7):1177–1182. [PubMed: 9314567] 
33. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM. 
Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor 
antigens. J Neurosurg. 1999; 90(6):1115–1124. [PubMed: 10350260] 
34. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, 
Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity 
and are effective against murine intracerebral melanoma. Neurosurgery. 2002; 50(1):158–164. 
[PubMed: 11844246] 
35. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. 
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat 
Med. 1996; 2(1):52–58. DOI: 10.1038/nm0196-52 [PubMed: 8564842] 
36. Nestle FO, Alijagic S, Gilliet M, Sun YS, Grabbe S, Dummer R, Burg G, Schadendorf D. 
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 
1998; 4(3):328–332. [PubMed: 9500607] 
37. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowers VA, Ragde H, Rogers M, Elgamal A, Kenny 
GM, Cobb OE, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific 
membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with 
hormone-refractory metastatic disease. Prostate. 1999; 38(1):73–78. [PubMed: 9973112] 
38. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, 
Schreiner D, von den Dresch P, et al. Vaccination with Mage-3A1 peptide-pulsed mature, 
monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some 
metastases in advanced stage IV melanoma. J Exp Med. 1999; 190(11):1669–1678. [PubMed: 
10587357] 
39. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, 
Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells 
generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000; 86(3):385–
392. [PubMed: 10760827] 
40. Fong L, Hou YF, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Altered 
peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. 
Proc Natl Acad Sci USA. 2001; 98(15):8809–8814. [PubMed: 11427731] 
41. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, 
Coquery S, Wittkowski KM, Bhardwaj N, et al. Immune and clinical responses in patients with 
metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 
61(17):6451–6458. [PubMed: 11522640] 
42. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, 
Fritsch PO, Romani N, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic 
melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived 
dendritic cells. J Exp Med. 2002; 195(10):1279–1288. [PubMed: 12021308] 
43. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, 
Caspar CB, Okada CY, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: 
clinical and immune responses in 35 patients. Blood. 2002; 99(5):1517–1526. [PubMed: 
11861263] 
44. Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M, Schneider A, Kaufmann AM, 
et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 
15 individual patients. J Cancer Res Clin Oncol. 2003; 129(9):521–530. [PubMed: 12898233] 
45. Salcedo M, Bercovici, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, 
Baron-Bodo V, Mallard E, et al. Vaccination of melanoma patients using dendritic cells loaded 
with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006; 55(7):819–829. 
[PubMed: 16187085] 
Filley and Dey Page 12
J Neurooncol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
46. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau 
J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical 
responses and MART-1 specific CD8(+) T-cell immunity. J Immunother. 2006; 29(5):545–557. 
[PubMed: 16971810] 
47. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger 
W, Schroder S, Horder MS, et al. Immunologic and clinical responses after vaccinations with 
peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006; 66(11):5910–
5918. DOI: 10.1158/0008-5472.CAN-05-3905 [PubMed: 16740731] 
48. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, 
Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N 
Engl J Med. 2010; 363(5):411–422. DOI: 10.1056/NEJMoa1001294 [PubMed: 20818862] 
49. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel PS, 
Belldegrun A, Cloughesy TF. Treatment of a patient by vaccination with autologous dendritic cells 
pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case 
report. Neurosurg Focus. 2000; 9(6):e8.
50. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson 
RC, Riedinger MS, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic 
cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001; 61(3):842–
847. [PubMed: 11221866] 
51. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of 
vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol 
Immunother. 2001; 50(7):337–344. DOI: 10.1007/s002620100205 [PubMed: 11676393] 
52. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Tsuchiya N, Homma J, Kobayashi T, Narita M, 
Takahashi M, Tanaka R. Vaccination of recurrent glioma patients with tumour lysate-pulsed 
dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003; 
89(7):1172–1179. [PubMed: 14520441] 
53. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed 
dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer 
Res. 2004; 64(14):4973–4979. [PubMed: 15256471] 
54. Rutkowski S, DeVleeschouwer S, Kaempgen E, Wolff JEA, Kuhl J, Demaerel P, Warmuth-Metz 
M, Flamen P, Van Calenbergh F, Plets C, et al. Surgery and adjuvant dendritic cell-based tumour 
vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004; 
91(9):1656–1662. DOI: 10.1038/sj.bjc.6602195 [PubMed: 15477864] 
55. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T. Vaccination of 
glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J 
Immunother. 2004; 27(6):452–459. DOI: 10.1097/00002371-200411000-00005 [PubMed: 
15534489] 
56. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita 
M, Takahashi M, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent 
glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005; 11(11):4160–4167. [PubMed: 
15930352] 
57. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng HS, Irvin D, 
Yu JS. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme 
patients. Cancer Res. 2008; 68(14):5955–5964. [PubMed: 18632651] 
58. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a phase I dendritic cell 
vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin 
Neurosci. 2008; 15(2):114–121. DOI: 10.1016/j.jocn.2007.08.007 [PubMed: 18083572] 
59. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bitjttebier P, Claes L, 
Goffin J, et al. Integration of autologous dendritic cell-based immunotherapy in the primary 
treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol. 
2010; 99(2):261–272. DOI: 10.1007/s11060-010-0131-y [PubMed: 20146084] 
60. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, 
Rhodes CH, Wishart HA, et al. Immune response in patients with newly diagnosed glioblastoma 
multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after 
Filley and Dey Page 13
J Neurooncol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
radiation chemotherapy. J Immunother. 2011; 34(4):382–389. DOI: 10.1097/CJI.
0b013e318215e300 [PubMed: 21499132] 
61. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett 
DL, Brown CK, et al. Induction of CD8(+) T-Cell responses against novel glioma–associated 
antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells 
and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients 
with recurrent malignant glioma. J Clin Oncol. 2011; 29(3):330–336. DOI: 10.1200/JCO.
2010.30.7744 [PubMed: 21149657] 
62. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK. A phase I/II clinical 
trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell 
tumor vaccine in patients with malignant glioma. J Clin Neurosci. 2011; 18(8):1048–1054. 
[PubMed: 21715171] 
63. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin 
J, Van Calenbergh F, et al. Integration of autologous dendritic cell-based immunotherapy in the 
standard of care treatment for patients with newly diagnosed glioblastoma: results of the 
HGG-2006 phase I/II trial. Cancer Immunol Immunother. 2012; 61(11):2033–2044. DOI: 10.1007/
s00262-012-1261-1 [PubMed: 22527250] 
64. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang HQ, Nuno MA, Richardson JE, Fan XM, 
Ji JF, Chu RM, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with 
newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013; 62(1):125–135. DOI: 
10.1007/s00262-012-1319-0 [PubMed: 22847020] 
65. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting 
of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen 
presentation on major histocompatibility complex class I products and peripheral CD8(+) T cell 
tolerance. J Exp Med. 2002; 196(12):1627–16338. DOI: 10.1084/jem.20021598 [PubMed: 
12486105] 
66. Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines—hope or 
hype? Nat Rev Immunol. 2014; 14(10):705–711. DOI: 10.1038/nri3727 [PubMed: 25190285] 
67. Thurner B, Roder C, Dieckmann D, Heuer H, Kruse M, Glaser A, Keikavoussi P, Kampgen E, 
Bender A, Schuler G. Generation of large numbers of fully mature and stable dendritic cells from 
leukapheresis products for clinical application. J Immunol Methods. 1999; 223(1):1–15. DOI: 
10.1016/S0022-1759(98)00208-7 [PubMed: 10037230] 
68. Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJA, van Hout-Kuijer M, Schaft N, Punt 
CJ, Figdor CG, Adema GJ, de Vries IJM. Commonly used prophylactic vaccines as an alternative 
for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood. 2010; 
116(4):564–574. DOI: 10.1182/blood-2009-11-251884 [PubMed: 20424184] 
69. Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and 
combination immunotherapies. Expert Rev Vaccines. 2013; 12(3):285–295. DOI: 10.1586/ERV.
13.22 [PubMed: 23496668] 
70. Engell-Noerregaard L, Hansen TH, Andersen MH, Straten PT, Svane IM. Review of clinical 
studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of 
correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009; 
58(1):1–14. DOI: 10.1007/s00262-008-0568-4 [PubMed: 18719915] 
71. Wimmers F, Schreibelt G, Skold AE, Figdor CG, De Vries IJM. Paradigm shift in dendritic cell-
based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC 
subsets. Front Immunol. 2014; doi: 10.3389/fimmu.2014.00165
72. Derer A, Frey B, Fietkau R, Gaipl U. Immune-modulating properties of ionizing radiation: 
rationale for the treatment of cancer by combination radiotherapy and immune checkpoint 
inhibitors. Cancer Immunol Immunother. 2016; 65(7):779–786. DOI: 10.1007/s00262-015-1771-8 
[PubMed: 26590829] 
73. Nikitina EY, Gabrilovich DI. Combination of γ-irradiation and dendritic cell administration 
induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced 
stage cancer. Int J Cancer. 2001; 94(6):825–833. [PubMed: 11745485] 
74. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JK, Liau LM. The 
TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T 
Filley and Dey Page 14
J Neurooncol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006; 176(1):
157–164. [PubMed: 16365406] 
75. Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B. 
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection. J 
Exp Med. 2013; 210(13):2803–2811. DOI: 10.1084/jem.20130678 [PubMed: 24277150] 
76. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, 
Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic 
melanoma. N Engl J Med. 2010; 363(8):711–723. DOI: 10.1056/NEJMoa1003466 [PubMed: 
20525992] 
77. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, 
Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 
(MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and 
immunologic correlates. J Clin Oncol. 2010; 28(19):3167–3175. DOI: 10.1200/JCO.2009.26.7609 
[PubMed: 20516446] 
78. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan 
CE, Gordon RA, Reed K, et al. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J 
Med. 2013; 369(2):122–133. DOI: 10.1056/NEJMoa1302369 [PubMed: 23724867] 
Filley and Dey Page 15
J Neurooncol. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. 
Demonstrating DC-T cell interaction. DCs provide three key signals to activate naïve T cells 
and initiate adaptive immune responses. First, DC surface p-MHC complexes are recognized 
by antigen-specific T cell receptors (TCRs). A second costimulatory interaction occurs 
between DC CD80/CD86 molecules and T cell CD28 molecules. T cells may also express 
CTLA-4 molecules, which interact with DC CD80/CD86 and transmit signals inhibitory to 
T cell activation. Depending on the presence of local cytokines, activated T cells may 
terminally differentiate along one of several specialized subtypes. Among these are Th1, 
Th2, Th17, and Treg lineages. Th1, Th2, and Th17 comprise the “activating” arms of T cell 
responses, and Treg cells form the “suppressive” arm. IL-12 stimulates the differentiation of 
Th1 cells, which produce IFN-g, an important activator of innate and adaptive immune 
responses. Their differentiation is inhibited by IL-4. IL-4 promotes the differentiation of Th2 
cells, which secrete IL-4, IL-5, IL-6, IL-10, and IL-13, activating eosinophils, mast cells, 
and B cells to support humoral immunity and parasite resistance. Th2 differentiation is 
inhibited by IFN-g. Th17 cells develop in the presence of TGF-b and IL-6 or IL-21. They 
secrete IL-17, IL-17F, IL-21, and IL-22 and play key roles in the development of 
autoimmune tissue inflammation and resistance to infection with extracellular bacteria. The 
presence of TGF-b promotes the development of regulatory T cells. Suboptimal p-MHC-
TCR or costimulatory interactions, which may occur through antigen presentation by 
immature DCs, and delivery of inhibitory signals via DC co-inhibitory molecules or 
CTLA-4 activation may also induce Treg cell differentiation. Treg cell development is 
inhibited by the IL-6. Tregs secrete IL-10 and TGF-b to suppress immune responses
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 m
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s t
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 c
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re
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s t
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 m
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BM
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 p
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 p
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s t
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m
or
 ly
sa
te
10
.1
 (5
.5 
in 
no
n-
re
sp
on
de
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 c
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lo
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ew
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 d
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ed
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β, 
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+
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m
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ew
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 d
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te
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m
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l. 
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ur
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nt
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O
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OA
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hA
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2,
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K
L-
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nd
 
gp
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0
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pe
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 p
ol
ar
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ed
 
D
C 
(m
atu
red
 w
ith
 
IL
-1
β, 
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F-
α, 
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N
-α
,
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N
-γ,
 
an
d 
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ly
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 + 
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nt
he
tic
 tu
m
or
 
pe
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es
; p
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an
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I
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nt
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, m
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 c
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 c
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BM
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rre
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s t
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 c
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 d
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 re
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rre
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ai
ns
te
m
 g
lio
m
a 
(1)
H
ER
2,
 T
RP
-2
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A
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A
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G
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l. 
[2
9]
I
6
G
BM
 (2
/4 
rec
urr
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sti
c 
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at
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 d
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 d
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 d
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